Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Relmada Therapeutics Inc

RLMD ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$4.80

▲ +1.05%

Market Cap $512.02M · Vol 355.93K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$512.02M

Small Cap

Div Yield

N/A

EPS Growth

+45.57%

YoY

RSI (14)

39.36

Momentum

Beta

0.44

vs Market

52W High

$7.99

39.92% below

52W Low

$0.59

713.56% above

Volume

355.93K

Avg 519.16K

P/B

4.09

Price-to-book

ROE

N/A

Return on equity

Free Float

92.69%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Relmada Therapeutics Inc (RLMD) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RLMD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.83%

-22.71%

-35.31%

+29.03%

YTD

-0.62%

+690.51%

+40.76%

-78.99%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-57,385,160.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-82.08% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.09
P/FCF	N/A
EPS Growth	+45.57%
Outstanding Shares	106.67M

Technical Indicators

50-Day SMA	$5.87
200-Day SMA	$5.36
RSI (14)	39.36
Beta	0.44
52-Week High	$7.99
52-Week Low	$0.59

Volume Today	355.93K
Avg Daily Volume (30D)	519.16K
Relative Volume	0.69x
Volatility (10D)	66.38
Volatility (30D)	64.05
Free Float	92.69%

Analyst Consensus

BUY

Current Price $4.80

Mean Target $12.67

52W Low$0.59 52W High$7.99

Current

Target

$0.59 $7.99

Current Analyst target

+163.89% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG003MKSL25

ISINUS75955J4022

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.